Small GTP binding protein Ras contributes to norepinephrine-induced mitogenesis of vascular smooth muscle cells

Prostaglandins and Other Lipid Mediators

Volumn 65, Issue 1, 2001, Pages 33-43

  Muthalif, Mubarack M ^a   Uddin, Mohammed R ^b   Fatima, Soghra ^a   Parmentier, Jean Hugues ^a   Khandekar, Zinat ^a   Malik, Kafait U ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b LeMoyne Owen College   (United States)

Author keywords

20 HETE; Farnesyl transferase; Mitogenesis; Norepinephrine; Ras; Vascular smooth muscle cells

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; BMS 191563; ICOSATETRAENOIC ACID; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NORADRENALIN; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; MITOGENESIS; NONHUMAN; PROTEIN LOCALIZATION; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ALKYL AND ARYL TRANSFERASES; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; MICROSCOPY, CONFOCAL; MITOGEN-ACTIVATED PROTEIN KINASES; MITOSIS; MUSCLE, SMOOTH, VASCULAR; NOREPINEPHRINE; PHOSPHORYLATION; RAS PROTEINS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0035042799     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(01)00112-5     Document Type: Article

References (34)

1. Hypertension and cardiovascular hypertrophy during chronic catecholamine infusion in rats
2. Replication of smooth muscle cells in vascular disease
3. Growth-stimulating effect of catecholamines on rat aortic smooth muscle cells in culture
4. 2 adrenergic receptors increase cell migration and decrease F-actin labeling in rat aortic smooth muscle cells
5. 2 in norepinephrine-induced arachidonic acid release in rabbit aortic smooth muscle cells
6. Activation of MAP kinases by arachidonic acid and its metabolites in VSMCs
7. 2+/calmodulin-dependent protein kinase II-induced MAP kinase activation in VSMC
8. 2-mediated activation of MAP kinase by angiotensin II
9. 2α-induced protein synthesis in smooth muscle cells
10. 1 adrenergic receptors activate phosphatidylinositol 3-kinase in human VSMC: Role in mitogenesis
11. 1- and β-adrenoceptors
12. Cytochrome P-450 metabolites mediate norepinephrine-induced mitogenic signaling
13. 1A adrenergic receptors in cultured smooth muscle cells of rabbit aorta
14. Isoprenoid modification and plasma membrane association: Critical factors for Ras oncogenicity
15. Protein prenylation: Molecular mechanisms and functional consequences
16. 21 Ras protein: Biological and biochemical significance of the cysteine nearest the carboxy terminus
17. Development of highly potent inhibitors of Ras FTase possessing cellular and in vivo activity
18. Inhibition of cellular Ras prevents smooth muscle cell proliferation after vascular injury in vivo
19. Pharmacology of smooth muscle cell replication
20. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors
21. The EGF receptor as central transducer of heterologous signalling systems
22. 21Ras farnesyl:protein transferase by Cys-AAX tetrapeptides
23. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956
24. Inhibition of Ras-targeted prenylation: Protein farnesyl transferase inhibitors revisited
25. Manumycin A, inhibitor of ras farnesyltransferase, inhibits proliferation and migration of rat VSMC
26. Ras-Cdc25 and Rho-Dbl binding assays: Complex formation in vitro
27. The Ras mutant D119N is both dominant negative and activated
28. Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP
29. 1-adrenergic receptor stimulation of mitogenesis in human VSMC: Role of tyrosine protein kinases and calcium in activation of MAP kinase
30. Pharmacological control of the mevalonate pathway: Effect on arterial smooth muscle cell proliferation
31. 53-independent manner
32. Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects
33. 53 wild type tumor cells
34. Cell cycle progression. New therapeutic target for vascular proliferative diseases